All In Biotech

Drug Trial Radar · NCT04713475

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered Into the Cisterna Magna of Pediatric Type 1 (Early Onset) and Type 2a (Late Onset) Infantile GM1 Gangliosidosis

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Mar 17, 2021

Primary completion

Feb 2028

Study completion Feb 2029

Sponsor

Lead sponsor
Gemma BiotherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PBGM01 is a gene therapy for GM1 gangliosidosis intended to deliver a functional copy of the GLB1 gene to the brain and peripheral tissues. This study will assess in a 2 part design the safety, tolerability and efficacy of PBGM01 in patients with early onset infantile (Type 1) and late onset infantile (Type 2a) GM1 gangliosidosis

Conditions

  • GM1 Gangliosidosis
  • GM1 Gangliosidosis, Type I
  • GM1 Gangliosidosis, Type 2
  • Beta-Galactosidase-1 (GLB1) Deficiency

Interventions

  • PBGM01Biological

    AAVhu68 viral vector

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Related AEs and SAEs as Characterized by CTCAEv5.0Time frame: Up to 5 years (multiple visits)
  2. Change from Baseline in Developmental Milestones as Assessed by the Bayley Scale of Infant and Toddler Development, Third EditionTime frame: From baseline to 2 years (multiple visits)

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Benioff Children's Hospital

    Oakland, California

  • University of Minnesota

    Minneapolis, Minnesota

  • Children's Hospital at St. Peter's University Hospital

    New Brunswick, New Jersey

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Hospital de Clínicas de Porto Alegre (HCPA)

    Porto Alegre, Brazil

  • Gazi University

    Ankara, Turkey (Türkiye)

  • Great Ormond Street Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.